Chargement en cours...
Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic Leukemia in the United States: A large population-based study
BACKGROUND: Despite approval of azacitidine in 2004 and decitabine in 2006 in the US for chronic myelomonocytic leukemia (CMML), overall survival (OS) benefit with hypomethylating agent (HMA) therapy is unclear. METHODS: We selected older adults (age ≥66 years) diagnosed with CMML during 2001–2011 f...
Enregistré dans:
| Publié dans: | Cancer |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6540984/ https://ncbi.nlm.nih.gov/pubmed/28621841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30814 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|